SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry

SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry

The purpose of the study is to understand Supplementary Protection Certificate (SPC) regulations associated with pharmaceutical products. In this study the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe have been reviewed. On one hand, this stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of intellectual property rights 2019-01, Vol.24 (1-2), p.5
Hauptverfasser: Joshi, Omkar, Roy, Archna, Janodia, Manthan
Format: Artikel
Sprache:eng
Schlagworte:
Generic drugs
Pharmaceutical industry
Regulation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1-2
container_start_page 5
container_title Journal of intellectual property rights
container_volume 24
creator Joshi, Omkar
Roy, Archna
Janodia, Manthan
description The purpose of the study is to understand Supplementary Protection Certificate (SPC) regulations associated with pharmaceutical products. In this study the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe have been reviewed. On one hand, this study provided insights into innovator strategies in managing product lifecycles and on the other hand, it also helped in studying perspective of generic drug industry. A survey amongst IP experts about SPC regulation have also been carried out. It is observed that there is a need to amend the SPC regulation to provide better clarity to both innovators and generic drug industry.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2282441147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2282441147</sourcerecordid><originalsourceid>FETCH-LOGICAL-p98t-af5b11aff6a7ccc8ddc403254c568858242c39c43f93e833b1ce8a89d1d1646a3</originalsourceid><addsrcrecordid>eNotjstqwzAURLVooSHNPwi6rcGyrmxpGUwfAUPTNPtwo0fr4FiuHpT8fV2a2QzDYYa5IYtSNaxoBMAdWcV4KmdxBnNekPePbUt39jMPmHo_PtL1iMMl9pF6R_9Yi9HSDn8ixdHQnUdzxok6H-j2C8MZtc2p1zjQzWhyTOFyT24dDtGurr4k--enfftadG8vm3bdFZOSqUAnjoyhczU2WmtpjIaSVwK0qKUUsoJKc6WBO8Wt5PzItJUolWGG1VAjX5KH_9kp-O9sYzqcfA7z-XioqrkOjEHDfwEtL0nl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2282441147</pqid></control><display><type>article</type><title>SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Joshi, Omkar ; Roy, Archna ; Janodia, Manthan</creator><creatorcontrib>Joshi, Omkar ; Roy, Archna ; Janodia, Manthan</creatorcontrib><description>The purpose of the study is to understand Supplementary Protection Certificate (SPC) regulations associated with pharmaceutical products. In this study the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe have been reviewed. On one hand, this study provided insights into innovator strategies in managing product lifecycles and on the other hand, it also helped in studying perspective of generic drug industry. A survey amongst IP experts about SPC regulation have also been carried out. It is observed that there is a need to amend the SPC regulation to provide better clarity to both innovators and generic drug industry.</description><identifier>ISSN: 0971-7544</identifier><language>eng</language><publisher>New Delhi: National Institute of Science Communication &amp; Information Resources</publisher><subject>Generic drugs ; Pharmaceutical industry ; Regulation</subject><ispartof>Journal of intellectual property rights, 2019-01, Vol.24 (1-2), p.5</ispartof><rights>Copyright National Institute of Science Communication &amp; Information Resources Jan-Mar 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Joshi, Omkar</creatorcontrib><creatorcontrib>Roy, Archna</creatorcontrib><creatorcontrib>Janodia, Manthan</creatorcontrib><title>SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry</title><title>Journal of intellectual property rights</title><description>The purpose of the study is to understand Supplementary Protection Certificate (SPC) regulations associated with pharmaceutical products. In this study the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe have been reviewed. On one hand, this study provided insights into innovator strategies in managing product lifecycles and on the other hand, it also helped in studying perspective of generic drug industry. A survey amongst IP experts about SPC regulation have also been carried out. It is observed that there is a need to amend the SPC regulation to provide better clarity to both innovators and generic drug industry.</description><subject>Generic drugs</subject><subject>Pharmaceutical industry</subject><subject>Regulation</subject><issn>0971-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotjstqwzAURLVooSHNPwi6rcGyrmxpGUwfAUPTNPtwo0fr4FiuHpT8fV2a2QzDYYa5IYtSNaxoBMAdWcV4KmdxBnNekPePbUt39jMPmHo_PtL1iMMl9pF6R_9Yi9HSDn8ixdHQnUdzxok6H-j2C8MZtc2p1zjQzWhyTOFyT24dDtGurr4k--enfftadG8vm3bdFZOSqUAnjoyhczU2WmtpjIaSVwK0qKUUsoJKc6WBO8Wt5PzItJUolWGG1VAjX5KH_9kp-O9sYzqcfA7z-XioqrkOjEHDfwEtL0nl</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Joshi, Omkar</creator><creator>Roy, Archna</creator><creator>Janodia, Manthan</creator><general>National Institute of Science Communication &amp; Information Resources</general><scope>E3H</scope><scope>F2A</scope></search><sort><creationdate>20190101</creationdate><title>SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry</title><author>Joshi, Omkar ; Roy, Archna ; Janodia, Manthan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p98t-af5b11aff6a7ccc8ddc403254c568858242c39c43f93e833b1ce8a89d1d1646a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Generic drugs</topic><topic>Pharmaceutical industry</topic><topic>Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joshi, Omkar</creatorcontrib><creatorcontrib>Roy, Archna</creatorcontrib><creatorcontrib>Janodia, Manthan</creatorcontrib><collection>Library &amp; Information Sciences Abstracts (LISA)</collection><collection>Library &amp; Information Science Abstracts (LISA)</collection><jtitle>Journal of intellectual property rights</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joshi, Omkar</au><au>Roy, Archna</au><au>Janodia, Manthan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry</atitle><jtitle>Journal of intellectual property rights</jtitle><date>2019-01-01</date><risdate>2019</risdate><volume>24</volume><issue>1-2</issue><spage>5</spage><pages>5-</pages><issn>0971-7544</issn><abstract>The purpose of the study is to understand Supplementary Protection Certificate (SPC) regulations associated with pharmaceutical products. In this study the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe have been reviewed. On one hand, this study provided insights into innovator strategies in managing product lifecycles and on the other hand, it also helped in studying perspective of generic drug industry. A survey amongst IP experts about SPC regulation have also been carried out. It is observed that there is a need to amend the SPC regulation to provide better clarity to both innovators and generic drug industry.</abstract><cop>New Delhi</cop><pub>National Institute of Science Communication &amp; Information Resources</pub></addata></record>
fulltext fulltext
identifier ISSN: 0971-7544
ispartof Journal of intellectual property rights, 2019-01, Vol.24 (1-2), p.5
issn 0971-7544
language eng
recordid cdi_proquest_journals_2282441147
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Generic drugs
Pharmaceutical industry
Regulation
title SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T18%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SPC%20Regulation,%20Analysis%20of%20SPC%20Case%20Laws%20and%20Roadmap%20for%20Pharmaceutical%20Industry&rft.jtitle=Journal%20of%20intellectual%20property%20rights&rft.au=Joshi,%20Omkar&rft.date=2019-01-01&rft.volume=24&rft.issue=1-2&rft.spage=5&rft.pages=5-&rft.issn=0971-7544&rft_id=info:doi/&rft_dat=%3Cproquest%3E2282441147%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2282441147&rft_id=info:pmid/&rfr_iscdi=true